Medical Xpress on MSN12d
Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease
Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS ...
FierceBiotech1d
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
Taiwan News8d
Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Size, Trends, and Growth Opportunities by Type, Treatment, End User, and Region, 2024-2032
Report Ocean, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023.
STAT1d
Fueled by a ‘fall off your chair’ discovery and $101 million, Trace launches to take on ALS
A surprise finding by two independent research teams and a venture capital mega-round have birthed a biotech looking to treat ...
Business Wire19h
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...
Natasha Alexenko, Who Exposed Backlog of Rape Cases, Dies at 51
Ten years after her sexual assault, she discovered that the evidence in her rape kit hadn’t been tested — and neither had ...
Medical Xpress13d
Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease
Citation: Study identifies 51 amyotrophic lateral sclerosis-associated mutations that could help diagnose the disease (2024, October 31) retrieved 8 November 2024 from https://medicalxpress.com ...
Rock stars set to play Light of Day’s 25th anniversary Bob's Birthday Bash
John Rzeznik, Brian Fallon, Pete Steinkopf, Dramarama, Willie Nile, Joe Grushecky and the Houserockers and more set for Bob's ...
Pharmabiz19h
Neurizon Therapeutics receives positive opinion on orphan medicinal product designation for NUZ-001 in Europe
for the treatment of Amyotrophic Lateral Sclerosis (ALS). The European Commission is scheduled to issue the official decision on the Orphan Designation in December. OMPD will offer Neurizon a range of ...